Logo

Rosetta Awarded Israeli Grant to Develop microRNA-targeting Cancer Drug

Aug 08, 2013
Premium

Rosetta Genomics this week announced that it has been awarded a $200,000 grant along with Ramot, Tel Aviv University’s technology-transfer company, to develop microRNA-targeting cancer drugs.

According to the company, the initial focus of the alliance will be on developing a mimic of miR-34a delivered using a polymeric carrier. The miRNA is a tumor suppressor downregulated in a variety of cancers, Rosetta said.

Notably, a miR-34a mimic developed by Mirna Therapeutics is already in the clinic as a cancer treatment (GSN 5/2/2013).

Filed under

Gene Editing, Gene Silencing, & CRISPR
Cancer
Rosetta Genomics
Companies: Mirna
RNAi
miRNA
Breaking News
The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.